Biotech Values

[drbio45]

Ohr Pharmaceutical, Inc. (NasdaqCM: OHRP), an ophthalmology research and development company, is hosting a Key Opinion Leader breakfast today, Friday, October 31, 2014, from 8:00 am-9:30 am Eastern Time in New York City. A live webcast and subsequent replay of the event will be available at http://lifesci.rampard.com/20141031 and will also be accessible through the Investors section of the Company’s website at www.ohrpharmaceutical.com.

Ohr hosted an analyst day last week. The data they presented is excellent. I know there are a lot of skeptics out there but this should be looked at with an open mind. The comparable in the market to look at is Ophthotech. This data is excellent compared to their's. If you listen to K. Bailey Freund one of the top retina docs in the country, the opht treatment may not be commercially viable.

The meeting will feature discussions by two retinal disease experts, K. Bailey Freund, MD, and Ohr’s Chief Medical Officer, Jason S. Slakter, MD.

Dr. Freund specializes in all retinal disorders and has been a principal investigator in several pivotal trials of novel treatments for retinal diseases, including macular degeneration, diabetic retinopathy, and retinal vascular and inflammatory diseases. He is a Clinical Associate Professor of Ophthalmology at the NYU School of Medicine and practices at New York Presbyterian Hospital, Manhattan Eye Ear & Throat Institute, and Vitreous-Retina-Macula Consultants of NY, the largest retina practice in the New York Metropolitan area.

Dr. Slakter, who currently serves as the Chief Medical Officer at Ohr, is an internationally recognized retinal and macular disease specialist and has played a major role in developing treatments for age-related macular degeneration, retinal vascular disease, diabetic retinopathy, and central serous chorioretinopathy. He is a Clinical Professor of Ophthalmology at NYU School of Medicine and practices at Vitreous-Retina-Macula Consultants of NY.